Search
Cloxacillin
go.drugbank.com/drugs/DB01147ApprovedInvestigationalVet approvedA semi-synthetic penicillin antibiotic which is a chlorinated derivative of [oxacillin].
Flucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
OP-145
go.drugbank.com/drugs/DB05672ExperimentalOP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.
Synonyms: -GLUTAMYL-L-ARGINYL-L-ISOLEUCYL-L-LYSYL-L-ARGINYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-VALYL-L-ARGINYL-L-PRO, L-ARGININE, L-ISOLEUCYLGLYCYL-L-LYSYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LYSYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-.ALPHA.IMMU-114
go.drugbank.com/drugs/DB18458InvestigationalIMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Zatolmilast
go.drugbank.com/drugs/DB14790InvestigationalBPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
Iodine I-125
go.drugbank.com/drugs/DB14804InvestigationalIodine I-125 is under investigation in clinical trial NCT00079417 (Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma).
Olendalizumab
go.drugbank.com/drugs/DB14834InvestigationalOlendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).
Cobomarsen
go.drugbank.com/drugs/DB14931InvestigationalCobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).
Diflomotecan
go.drugbank.com/drugs/DB16138InvestigationalDiflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).